Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05515874 · ClinicalTrials.gov registry record · Phase 4
Predicting Stroke Risk in ICAD With Novel MRI
A Phase 4 study of Intracranial Atherosclerosis, sponsored by Northwestern University.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 100
- Enrollment target
- 1
- Study location
NCT05515874 is a Phase 4 study of Intracranial Atherosclerosis that is actively recruiting participants, run by Northwestern University. The registered enrollment target is 100 participants. The trial reports 1 study location across 1 state.
The verdict
NCT05515874, a Phase 4 study of Intracranial Atherosclerosis, is actively recruiting participants, sponsored by Northwestern University.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 100 participants
- Enrollment target
- 1
- Study location
Study Summary
The cerebral and spinal vasculature possesses several unique properties: it is composed of relatively small vessels, it has a highly connected network architecture, and, due to the confined space around the brain, disruptions in flow (rupture, shunting, or blockage) can cause a clinical impact quickly. These features apply across various pathological conditions that alter the distribution of blood through the cerebral vasculature, such as aneurysm, intracranial atherosclerotic disease (ICAD) and arteriovenous malformation (AVM) as well as others. Neurovascular disease is a leading cause of mortality due to stroke in the United States and encompasses a broad range of pathologies including but not limited to cerebral arteriovenous malformation, intracranial atherosclerotic disease, intracranial aneurysms and other neurovascular abnormalities. Novel modalities for assessing disease states in patients with these pathologic conditions are constantly being developed and the understanding of risk factors, disease progression, and effective therapy is rapidly evolving. Neurovascular imaging is at the forefront of this progress. The identification of new predictive biomarkers regarding the risk of rupture, progression, or recurrence will improve prognosis and treatment planning. In this study, there will be evaluation of the various types of brain lesions and different treatment options that have been used by the treating physicians and, grade outcome based on the standard of care MRI imaging. This can help the Investigators stratify the treatment routes, that are better than the other by assessing the mortality and morbidity rates. Investigators are evaluating intracranial lesions and their treatment outcomes can help analyze which standard of care treatment is better than the others at a setting like Northwestern.
Conditions Studied
Interventions
- DRUG Feraheme
Study Locations (1)
Illinois
- Northwestern University - Chicago
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 100 participants |
| Start Date | 2021-08-16 |
| Est. Completion | 2026-03-30 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05515874
The ClinicalTrials.gov registry entry for NCT05515874 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 100 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Intracranial Atherosclerosis appearing as the primary indexed condition, and to 1 intervention - of which Feraheme is the first listed.
NCT05515874 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT05515874 about?
NCT05515874 is a clinical study titled "Predicting Stroke Risk in ICAD With Novel MRI". The cerebral and spinal vasculature possesses several unique properties: it is composed of relatively small vessels, it has a highly connected network architecture, and, due to the confined space around the brain, disruptions in flow (rupture, shunting, or blockage) can cause a clinical impact quick...
What is the current status of trial NCT05515874?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 100 participants. The study started on 2021-08-16. Estimated completion is 2026-03-30.
What conditions does trial NCT05515874 study?
This clinical trial studies the following conditions: Intracranial Atherosclerosis.
What interventions are being tested in trial NCT05515874?
The interventions under investigation include: Feraheme (DRUG).
Who is sponsoring clinical trial NCT05515874?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05515874 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.